Pharmaceutical formulations
AssigneeNovo Nordisk A/S
InventorsTommy Sander, Christian Poulsen, Rosa Rebecca Erritzoee Hansen
Life of this patent
Estimating the term…
Abstract
Disclosed herein are an aqueous pharmaceutical formulation comprising cagrilintide and an aqueous formulation comprising semaglutide. The compositions of these two pharmaceutical formulations allow for their presentation in, and administration using, the dual-chamber medical device disclosed herein. Individuals with diseases, such as diabetes and/or obesity and/or related co-morbidities, may benefit from the co-administration of semaglutide and cagrilintide, and/or of the two liquid pharmaceutical formulations disclosed herein, using the medical device disclosed herein.
Claims30
An aqueous cagrilintide formulation comprising:
- cagrilintide;
- a buffer which is:
- glutamic acid/glutamate, in a concentration of about 2-10 mM;
- or lactic acid/lactate, in a concentration of about 2-35 mM;
- or acetic acid/acetate, in a concentration of about 2-10 mM;
- and
- a pH of 3.5-4.5.
An aqueous semaglutide formulation comprising:
- semaglutide;
- phosphate, in a concentration of more than 15 mM and less than or equal to 45 mM;
- and
- a pH of 7.0-8.0.
A medical device comprising a first chamber and a second chamber, wherein the first chamber comprises an aqueous semaglutide formulation and the second chamber comprises an aqueous cagrilintide formulation, wherein the aqueous semaglutide formulation comprises:
- semaglutide;
- phosphate, in a concentration of more than 15 mM and less than or equal to 45 mM;
- and
- a pH of 7.0-8.0, and
- wherein the cagrilintide formulation comprises cagrilintide;
- a buffer which is:
- glutamic acid/glutamate, in a concentration of about 2-10 mM;
- or lactic acid/lactate, in a concentration of about 2-35 mM;
- or acetic acid/acetate, in a concentration of about 2-10 mM;
- and
- a pH of 3.5-4.5.
A method of administering a fixed-dose combination of 0.025-5.0 mg cagrilintide and 0.05-5.0 mg semaglutide, comprising administering such combination subcutaneously, in a single injection.
Dependencies are inferred from the claim text.